Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients

2011 ◽  
Vol 52 (2) ◽  
pp. 173-180 ◽  
Author(s):  
Goran Abdulqadhr ◽  
Daniel Molin ◽  
Gunnar Åström ◽  
Madis Suurküla ◽  
Lars Johansson ◽  
...  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Gil-Sun Hong ◽  
Eun Jin Chae ◽  
Jin-Sook Ryu ◽  
Sun Young Chae ◽  
Hyo Sang Lee ◽  
...  

Abstract Background We prospectively evaluated the diagnostic utility of whole-body diffusion-weighted imaging with background body signal suppression and T2-weighted short-tau inversion recovery MRI (WB-DWIBS/STIR) for the pretherapeutic staging of indolent lymphoma in 30 patients. Methods This prospective study included 30 treatment-naive patients with indolent lymphomas who underwent WB-DWIBS/STIR and conventional imaging workup plus biopsy. The pretherapeutic staging agreement, sensitivity, and specificity of WB-DWIBS/STIR were investigated with reference to the multimodality and multidisciplinary consensus review for nodal and extranodal lesions excluding bone marrow. Results In the pretherapeutic staging, WB-DWIBS/STIR showed very good agreement (κ = 0.96; confidence interval [CI], 0.88–1.00), high sensitivity (93.4–95.1%), and high specificity (99.0–99.4%) for the whole-body regions. These results were similar to those of 18F-FDG-PET/CT, except for the sensitivity for extranodal lesions. For extranodal lesions, WB-DWIBS/STIR showed higher sensitivity compared to 18F-FDG-PET/CT for the whole-body regions (94.9–96.8% vs. 79.6–86.3%, P = 0.058). Conclusion WB-DWIBS/STIR is an effective modality for the pretherapeutic staging of indolent lymphoma, and it has benefits when evaluating extranodal lesions, compared with 18F-FDG-PET/CT.


2020 ◽  
Vol 99 (12) ◽  
pp. 2869-2880
Author(s):  
Charles Mesguich ◽  
Cyrille Hulin ◽  
Valerie Latrabe ◽  
Axelle Lascaux ◽  
Laurence Bordenave ◽  
...  

Radiology ◽  
2008 ◽  
Vol 248 (2) ◽  
pp. 643-654 ◽  
Author(s):  
Yoshiharu Ohno ◽  
Hisanobu Koyama ◽  
Yumiko Onishi ◽  
Daisuke Takenaka ◽  
Munenobu Nogami ◽  
...  

2014 ◽  
Vol 40 (6) ◽  
pp. 1655-1665 ◽  
Author(s):  
Masatoyo Nakajo ◽  
Masayuki Nakajo ◽  
Yoshihiko Fukukura ◽  
Megumi Jinguji ◽  
Toshikazu Shindo ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Alessandro Stecco ◽  
Francesco Buemi ◽  
Martina Quagliozzi ◽  
Mariangela Lombardi ◽  
Alberto Santagostino ◽  
...  

Background. The purpose of this study was to compare the accuracy of whole-body MRI with diffusion-weighted sequences (WB-DW-MRI) with that of18F-FDG-PET/CT in the staging of patients with primary gastrointestinal lymphoma.Methods. This retrospective study involved 17 untreated patients with primary abdominal gastrointestinal lymphoma. All patients underwent18F-FDG-PET/CT and WB-DW-MRI. Histopathology findings or at least 6 months of clinical and radiological follow-up was the gold standard. The Musshoff-modified Ann Arbor system was used for staging, and diagnostic accuracy was evaluated on a per-node basis.Results. WB-DW-MRI exhibited 100% sensitivity, 96.3% specificity, and 96.1% and 100% positive and negative predictive values (PPV and NPV), respectively. The sensitivity, specificity, and PPV and NPV of PET/CT were 95.9%, 100%, and 100% and 96.4%, respectively. There were no statistically significant differences between the two techniquesp=0.05. The weighted kappa agreement statistics with a 95% confidence interval were 0.97 (0.95–0.99) between the two MRI readers and 0.87 (0.82–0.92) between the two methods.Conclusions. WB-DW-MRI appears to have a comparable diagnostic value to18F-FDG-PET/CT in staging patients with gastrointestinal lymphoma.


2012 ◽  
Vol 22 (7) ◽  
pp. 1479-1487 ◽  
Author(s):  
Michael Soussan ◽  
Gaëtan Des Guetz ◽  
Vincent Barrau ◽  
Vanessa Aflalo-Hazan ◽  
Gabriel Pop ◽  
...  

2011 ◽  
Vol 196 (3) ◽  
pp. 662-669 ◽  
Author(s):  
Henriëtte M. E. Quarles van Ufford ◽  
Thomas C. Kwee ◽  
Frederik J. Beek ◽  
Maarten S. van Leeuwen ◽  
Taro Takahara ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1938
Author(s):  
Charles Mesguich ◽  
Valérie Latrabe ◽  
Cyrille Hulin ◽  
Axelle Lascaux ◽  
Laurence Bordenave ◽  
...  

To compare the prognostic values of 18-FDG PET/CT (FDG-PET) and Whole-Body MRI with Diffusion-Weighted Imaging (WB-DW-MRI) in the evaluation of treatment response of Multiple Myeloma (MM) patients eligible for ASCT. Thirty patients with newly diagnosed MM prospectively underwent FDG-PET and WB-DW-MRI at baseline, after induction chemotherapy and after ASCT. Response on WB-DW-MRI was evaluated with the MY-RADS criteria. FDG-PET was considered positive if residual uptake was superior to liver uptake. Imaging results were not used for treatment modification. The impact of imaging results on PFS was analyzed. After a median follow-up of 32 months, 10 patients relapsed. With WB-DW-MRI, post-induction examination was positive in 3/25 and post-ASCT examination was positive in 3/27 patients. However, neither study showed prognostic impact on PFS. FDG-PET was positive in 5/22 post-induction and 3/26 patients post-ASCT, respectively. Positivity of FDG-PET, post-induction or post-ASCT, was associated with a shorter PFS (post-induction: median PFS 19 months vs. not reached, log-rank p = 0.0089; post-ASCT: median PFS 18 months vs. not reached, log-rank p = 0.0005). Preliminary results from this small, single-center, prospective study show that, whether performed post-induction or post-ASCT, FDG-PET has a higher prognostic value than WB-DW-MRI for treatment response evaluation of newly diagnosed MM.


Sign in / Sign up

Export Citation Format

Share Document